fbpx Gatekeeper Innovation Named Awardee in Pill Protect QuickFire Challenge: Designing for Medication Safety at Safe Kids’ PrevCon - News | JLABS

Gatekeeper Innovation Named Awardee in Pill Protect QuickFire Challenge: Designing for Medication Safety at Safe Kids’ PrevCon

July 12, 2021 -
14 days ago
Other news

July 12, 2021 —Johnson & Johnson Innovation, together with Johnson & Johnson’s Office of the Chief Medical Officer (OCMO) and Scientific Education and Patient Advocacy (SEPA), in coordination with the Centers for Disease Control and Prevention PROTECT Initiative, announced today that Gatekeeper Innovation has been selected as the awardee in the Pill Protect QuickFire Challenge: Designing for Medication Safety. The challenge invited visionaries to submit ideas aiming to prevent or reduce the accidental accessing by children of medications in pill minders, pill organizers or pill dispensers.

To help advance its research, Gatekeeper Innovation will receive a total of $100,000 in grant funding, access to the global JLABS network, and mentorship from experts across the Johnson & Johnson Family of Companies *

Gatekeeper Innovation Gatekeeper Innovation is aiming to improve medication storage by developing two redesigned pill minders that seek to be more cost-effective, user-friendly, and child resistant. The company is aiming to prevent accidental medicine poisoning in children under the age of six with the introduction of its Rx Locking pill minder to promote safer medicine storage in the home.

The QuickFire Challenges are managed by Johnson & Johnson Innovation — JLABS, with the goal to help address today’s greatest health care challenges. A follow-up QuickFire Challenge focused on child-resistant unit dose technologies will be announced shortly.

* Subject to the execution of the necessary documentation and award agreement.

About Johnson & Johnson Office of the Chief Medical Officer

The Johnson & Johnson Office of the Chief Medical Officer (OCMO) is an internal global team of medical and scientific professionals, including safety experts, from all three sectors of Johnson & Johnson. Functionally independent from commercial or R&D interests, the OCMO is focused on the safety of products through people-driven processes, initiatives and policies that are reinforced by a single medical safety standard. Established in 2013, the OCMO also works to advance evidence and science-based decision-making that is driven by bioethical principles and values.


Related content